stoxline Quote Chart Rank Option Currency Glossary
  
Natera, Inc. (NTRA)
91.46  1 (1.11%)    03-28 16:00
Open: 90.13
High: 92.42
Volume: 971,009
  
Pre. Close: 90.46
Low: 89.2
Market Cap: 10,898(M)
Technical analysis
2024-03-28 4:53:15 PM
Short term     
Mid term     
Targets 6-month :  112.4 1-year :  131.29
Resists First :  96.23 Second :  112.4
Pivot price 90.47
Supports First :  79.96 Second :  69.9
MAs MA(5) :  91.12 MA(20) :  90.31
MA(100) :  67.38 MA(250) :  56.66
MACD MACD :  3.9 Signal :  4.6
%K %D K(14,3) :  42.4 D(3) :  44.9
RSI RSI(14): 65.2
52-week High :  96.23 Low :  36.9
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NTRA ] has closed below upper band by 32.1%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 92.51 - 92.86 92.86 - 93.27
Low: 88.24 - 88.62 88.62 - 89.05
Close: 90.75 - 91.36 91.36 - 92.07
Company Description

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Headline News

Fri, 29 Mar 2024
Natera, Inc. (NASDAQ:NTRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Wed, 27 Mar 2024
Natera, Inc. (NASDAQ:NTRA) Shares Acquired by Assenagon Asset Management S.A. - MarketBeat

Mon, 25 Mar 2024
Natera, Inc. (NASDAQ:NTRA) Shares Sold by Artemis Investment Management LLP - MarketBeat

Mon, 25 Mar 2024
Public Employees Retirement System of Ohio Trims Position in Natera, Inc. (NASDAQ:NTRA) - Defense World

Mon, 25 Mar 2024
Natera, Inc. (NASDAQ:NTRA) Stock Position Reduced by Vanguard Group Inc. - Defense World

Fri, 22 Mar 2024
Natera: Capitalizing On The Positive Momentum Of Personalized Medicine (NASDAQ:NTRA) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Diagnostics & Research
Shares Out 121 (M)
Shares Float 116 (M)
Held by Insiders 4.1 (%)
Held by Institutions 95.8 (%)
Shares Short 8,550 (K)
Shares Short P.Month 7,840 (K)
Stock Financials
EPS -3.78
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.4
Profit Margin -40.2 %
Operating Margin -27.2 %
Return on Assets (ttm) -19.7 %
Return on Equity (ttm) -59.2 %
Qtrly Rev. Growth 43.2 %
Gross Profit (p.s.) 0
Sales Per Share 8.94
EBITDA (p.s.) -3.52
Qtrly Earnings Growth 0 %
Operating Cash Flow -247 (M)
Levered Free Cash Flow -183 (M)
Stock Valuations
PE Ratio -24.2
PEG Ratio 0
Price to Book value 14.29
Price to Sales 10.22
Price to Cash Flow -44.73
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android